Srikala Sridhar, MD; University of Toronto, Princess Margaret Cancer Centre; 5Live; #ASCOGU21

6:49

COVID-19: Impact on Caring for Your Patients With Genitourinary Cancers_ Episode 2

55:10

Thomas Powles, MD, MRCP; Barts Cancer Center 5Live #ASCO20

2:50

Key insights on IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).

Neal Shore, MD, FACS; Carolina Urologic Research Center 5Live #ASCO20

4:58

Key Insights on HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.

Elizabeth R. Plimack, MD; Fox Chase Cancer Center 5Live #ASCO20

2:47

Key insights on Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.

Episode 1 - COVID-19: Impact on Caring for Your Patients With Genitourinary Cancers

58:36

Neal Shore, MD, FACS

27:14

Presentation on Recent Advances in the Treatment of mHSPC and nmCRPC: New Options to Delay Progression to mCRPC from ASCO 2019 satellite symposium.

Charles Ryan, MD

18:51

Presentation on Optimizing Outcomes: Management of Cardiovascular Risk Factors from ASCO 2019 satellite symposium.

Daniel Petrylak, MD

30:05

Presentation on Biomarker-Directed Therapy in Prostate Cancer from ASCO 2019 satellite symposium.

Charles Ryan, MD

23:55

Presentation on New Agents and New Targets for the Treatment of mCRPC from ASCO 2019 satellite symposium.

Daniel Petrylak, MD, Karim Fizazi, MD, PhD #ASCO GU2019

18:19

Podium to Practice: Current and Future Treatment Options in Prostate Cancer - Impact of Metastases and Hormone Sensitivity presented at the ASCO GU 2019 Conference.